Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Deferred Taxes (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Deferred Taxes for 15 consecutive years, with -$25000.0 as the latest value for Q4 2025.

  • Quarterly Deferred Taxes fell 110.68% to -$25000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7000.0 through Dec 2025, down 102.69% year-over-year, with the annual reading at -$7000.0 for FY2025, 102.69% down from the prior year.
  • Deferred Taxes for Q4 2025 was -$25000.0 at Anika Therapeutics, down from $3000.0 in the prior quarter.
  • The five-year high for Deferred Taxes was $2.4 million in Q2 2021, with the low at -$2.8 million in Q4 2021.
  • Average Deferred Taxes over 5 years is -$655500.0, with a median of -$228500.0 recorded in 2022.
  • Peak annual rise in Deferred Taxes hit 261.84% in 2021, while the deepest fall reached 1055.19% in 2021.
  • Over 5 years, Deferred Taxes stood at -$2.8 million in 2021, then soared by 36.1% to -$1.8 million in 2022, then dropped by 3.6% to -$1.8 million in 2023, then soared by 112.7% to $234000.0 in 2024, then plummeted by 110.68% to -$25000.0 in 2025.
  • According to Business Quant data, Deferred Taxes over the past three periods came in at -$25000.0, $3000.0, and -$3000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.